SMARCB1 and neoplasm: As expected, SMARCA4 expression levels were reduced, whereas SMARCB1 expression levels were higher in SMARCA4-deficient tumor samples compared to all other ATRT subgroups (Supplementary Fig. 4a,b, online resource).